Revance Therapeutics (RVNC)
NASDAQ:RVNC
Holding RVNC?
Track your performance easily

Revance Therapeutics (RVNC) Financial Statements

608 Followers

Revance Therapeutics Financial Overview

Revance Therapeutics's market cap is currently ―. The company's EPS TTM is $-3.186; its P/E ratio is -1.47; Revance Therapeutics is scheduled to report earnings on November 5, 2024, and the estimated EPS forecast is $-0.27. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue$ 65.39M$ 51.94M$ 69.80M$ 56.78M$ 58.13M
Gross Profit$ 47.75M$ 37.02M$ 52.33M$ 37.36M$ 36.83M
EBIT$ -32.22M$ -44.27M-$ -131.95M$ -59.54M
EBITDA$ -28.66M$ -42.89M-$ -131.16M$ -56.94M
Net Income Common Stockholders$ -37.47M$ -53.15M$ -55.70M$ -141.18M$ -67.32M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 232.24M$ 277.07M$ 253.91M$ 300.25M$ 320.00M
Total Assets$ 494.80M$ 508.12M$ 478.45M$ 532.49M$ 597.53M
Total Debt$ 491.64M$ 475.78M$ 478.43M$ 487.90M$ 432.39M
Net Debt$ 259.39M$ 198.71M$ 224.52M$ 187.65M$ 112.39M
Total Liabilities$ 624.54M$ 606.79M$ 630.06M$ 638.69M$ 570.75M
Stockholders Equity$ -160.75M$ -98.67M$ -151.60M$ -106.20M$ 26.79M
Cash Flow-
Free Cash Flow$ -41.60M$ -67.65M-$ -55.47M$ -53.10M
Operating Cash Flow$ -41.13M$ -65.94M$ -42.73M$ -50.96M$ -53.36M
Investing Cash Flow$ -6.89M$ -31.71M$ 2.37M$ 51.59M$ -39.53M
Financing Cash Flow$ -3.41M$ 92.83M$ -1.63M$ 37.46M$ 97.47M
Currency in USD

Revance Therapeutics Earnings and Revenue History

Revance Therapeutics Debt to Assets

Revance Therapeutics Cash Flow

Revance Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis